63 articles, transcripts, and reports
Johnson & Johnson (NYSE: JNJ) has adopted a slow and steady approach in its COVID vaccine research, which is one of the few programs for…
Johnson & Johnson (NYSE: JNJ) Q3 2020 earnings call dated Oct. 13, 2020 Corporate Participants: Christopher DelOrefice — Vice President of Investor Relations Joseph J. Wolk — Executive Vice…
Johnson & Johnson (NYSE: JNJ) reported third-quarter 2020 financial results before the opening bell on Tuesday. The pharmaceutical giant reported a 2% increase in Q3…
Johnson & Johnson (NYSE: JNJ) Q2 2020 earnings call dated July 16, 2020 Corporate Participants: Chris DelOrefice — Vice President, Investor Relations Paul Stoffels — Vice Chairman of the…
Johnson & Johnson (NYSE: JNJ) saw revenue and earnings decline for the second quarter of 2020 but both the top and bottom line numbers came…
Johnson & Johnson (NYSE: JNJ) reported second quarter 2020 earnings results today. Reported sales decreased 10.8% to $18.3 billion. GAAP earnings fell 35% to $3.6…
Johnson & Johnson (JNJ) Q1 2020 earnings call dated Apr. 14, 2020. Corporate Participants: Chris DelOrefice — Vice President, Investor Relations Alex Gorsky — Chairman, Board of Directors and…
Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as…
Johnson & Johnson (NYSE: JNJ) Q4 2019 Earnings Conference Call Jan. 22, 2020 Corporate Participants: Christopher DelOrefice — Vice President of Investor Relations Alex Gorsky — Chairman, Board of Directors…
Johnson & Johnson (NYSE: JNJ) topped earnings estimates for the fourth quarter of 2019 while revenues fell short of expectations. The shares were down 1.5%…
